Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Publisher's Note: There is a Blood Commentary on this article in this issue.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Langerak, Anton W., Ritgen, Matthias, Goede, Valentin, Robrecht, Sandra, Bahlo, Jasmin, Fischer, Kirsten, Steurer, Michael, Trněný, Marek, Mulligan, Stephen P., Mey, Ulrich J. M., Trunzer, Kerstin, Fingerle-Rowson, Günter, Humphrey, Kathryn, Stilgenbauer, Stephan, Böttcher, Sebastian, Brüggemann, Monika, Hallek, Michael, Kneba, Michael, van Dongen, Jacques J. M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Letter to Blood
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6356981/
https://ncbi.nlm.nih.gov/pubmed/30455380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-03-839688
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados